查找临床试验
已按「遗传性视网膜病变」检索，对应国际通用词 inherited retinal disease
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 11:18，每 5 分钟自动同步Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation
China
年龄 18 Years – 不限
Chigenovo Co., Ltd
Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients
China
年龄 18 Years – 不限
Zhongshan Ophthalmic Center, Sun Yat-sen University
Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
China
年龄 6 Months – 不限
Eye & ENT Hospital of Fudan University
Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
China
年龄 不限 – 不限
Wang Yusheng
A Study of LX107 Gene Therapy in AIPL1-IRD Patients
China
年龄 4 Years – 不限
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients
China
年龄 18 Years – 65 Years
Zhongmou Therapeutics
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
United States、Australia、China
年龄 18 Years – 65 Years
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Safety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy
China
年龄 18 Years – 55 Years
Peking Union Medical College Hospital
High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
China
年龄 1 Year – 12 Years
Eye & ENT Hospital of Fudan University
Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
China
年龄 不限 – 不限
Sun Yat-sen University
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
United States、China
年龄 6 Years – 50 Years
HuidaGene Therapeutics Co., Ltd.
An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease
China
年龄 6 Years – 17 Years
HuidaGene Therapeutics Co., Ltd.